Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 15/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | KIF5B | P33176 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876318 | 0.94 | PLK4 (0.51) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876216 | 0.92 | PLK4 (0.52) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876231 | 0.91 | RET (0.45) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25875939 | 0.91 | RET (0.44) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25875987 | 0.89 | RET (0.47) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876277 | 0.89 | RET (0.43) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876081 | 0.89 | RET (0.43) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876039 | 0.89 | RET (0.43) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25875753 | 0.86 | RET (0.46) | PLK4RETJAK2KIF5BKDR | |
| SCHEMBL25876129 | 0.86 | PLK4 (0.46) | PLK4RETJAK2KIF5BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PLK4 1763/4885RET 1/4885JAK2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.